Trial Profile
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 30 Nov 2018 Status changed from active, no longer recruiting to discontinued.
- 22 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2018 Planned End Date changed from 23 Apr 2019 to 1 Sep 2019.